Thirty children with leukemia underwent allogeneic bone marrow transplantation (BMT) following a radiation-free preparative regimen, from July 1988 to January 1996. Twelve males and 18 females, ages 9 months to 15 years (median 8.5 years), received busulfan (BU, 4 mg/kg/day for 4 days by mouth), followed by melphalan (L-PAM, 60-70 mg/m 2 /day i.v. for 3 days), and infusion of allogeneic marrow from an HLA-matched related donor. Diagnoses included acute myelogenous leukemia (n = 20), acute lymphoblastic leukemia (n = 8) and chronic myelogenous leukemia (n = 2). Twenty-five patients were transplanted in first complete remission (CR), three in second CR, and two patients with chronic myelogenous leukemia in the first chronic phase. Graftversus-host disease (GVHD) prophylaxis consisted of methotrexate (MTX) alone in 27 patients and short-term MTX and cyclosporin A in three patients. Engraftment was achieved in all patients. Toxicities were mild or moderate. Six patients developed acute GVHD: four had grade I and two had grade II. Chronic GVHD was documented in eight patients. Three patients relapsed. As of September 1997, 27 patients were alive and well at 22-110 months (median 61) of follow-up. The disease-free survival rate at 5 years after BMT was 90%. A regimen consisting of high-dose BU and L-PAM without total body irradiation is useful for conditioning for allogeneic BMT in children with leukemia. Keywords: childhood; non-TBI regimen; bone marrow transplantation; leukemia; melphalan Considerable advances have been made over the last decade in the treatment of childhood leukemia. However, the cure rate for acute myelogenous leukemia (AML) 1-3 and highrisk group acute lymphoblastic leukemia (ALL) 4,5 remains unacceptable despite further intensive post-remission treatment. Bone marrow transplantation (BMT) appears to represent a therapeutic option with curative potential. However, total body irradiation (TBI) may induce late toxic effects, including cataracts, endocrinologic disturbances such as decreased growth, 6,7 and secondary malignancies. (CY) has demonstrated antileukemic activity similar to regimens including TBI, 9 and shown efficacy without an increase in regimen-related mortality.
Considerable advances have been made over the last decade in the treatment of childhood leukemia. However, the cure rate for acute myelogenous leukemia (AML) [1] [2] [3] and highrisk group acute lymphoblastic leukemia (ALL) 4, 5 remains unacceptable despite further intensive post-remission treatment. Bone marrow transplantation (BMT) appears to represent a therapeutic option with curative potential. However, total body irradiation (TBI) may induce late toxic effects, including cataracts, endocrinologic disturbances such as decreased growth, 6, 7 and secondary malignancies. 8 The combination of busulfan (BU) and cyclophosphamide
Correspondence: Dr T Matsuyama, 3-35, Michishita-cho, Nakamura-ku, Nagoya, 453 Japan Received 28 October 1997; accepted 14 February 1998 (CY) has demonstrated antileukemic activity similar to regimens including TBI, 9 and shown efficacy without an increase in regimen-related mortality. 10 Melphalan (L-PAM) has demonstrated a dose-response effect in highdose regimens for relapsed AML and ALL. 11 The greater antileukemic effect has been obtained in the L-PAM/TBI regimen compared with the CY/TBI regimen. 12 Based on these reports the BU/L-PAM regimen was used in our study. Here, we report outcomes in 30 leukemia patients who were conditioned with a BU/L-PAM regimen prior to marrow transplantation from HLA-identical related donors.
Patients and methods
From July 1988 to January 1996, 30 children underwent BMT following the BU/L-PAM regimen without TBI. Twenty-two of them were referred from other institutes. Patients with AML were treated according to protocols that were chiefly combinations of VP-16, cytosine arabinoside (Ara-C) and anthracycline. Patients with ALL were treated with various protocols. In two patients with chronic myelogenous leukemia (CML), one was maintained with BU and 6-mercaptopurine and another with hydroxyurea and interferon-␣. Patients with AML who achieved complete remission (CR) and those with CML in chronic phase who had an HLA-matched and mixed leukocyte culture compatible related donor were offered BMT (n = 22). Of the ALL patients three were non-T, non-B ALL with white blood cell (WBC) counts greater than 100 × 10 9 /l, one was T-ALL with a WBC count greater than 200 × 10 9 /l, two patients with non-T, non-B ALL were unable to receive scheduled therapy, because prolonged aplasia caused severe infection and delay in commencing subsequent chemotherapy, and two patients had additional myeloid markers. Three patients were transplanted in second CR; one had a prolonged pneumonia with residual lesions, one suffered from cardiomyopathy with cardiomegaly, and the other was 2 years of age and had already received 24 Gy cranial irradiation.
The median time from diagnosis to BMT was 7 months (range 3-119 months). Clinical characteristics of the 30 patients are shown in Table 1 .
Graft-versus-host disease (GVHD) prophylaxis
GVHD prophylaxis consisted of methotrexate (MTX) only (15 mg/m 2 on day +1, and 10 mg/m 2 on days +3, +6, +11 and weekly thereafter until day +60) in 27 patients who were transplanted from HLA-matched sibling donors. Three AML patients who were transplanted from a phenotypically HLA-identical mother received cyclosporin A (CsA) combined with a short course of MTX on days +1, +3, +6 and +11. CsA was begun on day +3 after transplant and given at 1.5 mg/kg every 12 h until patients were able to tolerate oral intake. CsA was then given orally at 3 mg/kg every 12 h for 6 months. It was then tapered and stopped 1 year after transplant. Folinic acid was given 3 mg orally in divided doses on the next day of MTX injection to prevent mucositis caused by MTX.
Supportive therapy
Transplants were carried out in a laminar airflow rooms. All patients received oral sulfamethoxazole and trimethoprim and amphotericin B from 3 days before BMT until at least 1 year after transplant. Prophylactic intravenous fosfomycin was given from 7 days before transplant until granulocyte recovery. Oral acyclovir was given in doses of 10-20 mg/kg (300-1000 mg/day) every day until 90 days after transplant to prevent herpes simplex and varicella zoster virus infection. All patients received intravenous cytomegalovirus (CMV) immunoglobulin at a dose of 2.5 to 5 g per week until day +90 to prevent CMV infection. The broad-spectrum antibiotics imipenem-cilastatin sodium and fluconazole were initiated for temperatures у38°C. Six patients with ALL were treated with granulocyte colonystimulating factor (G-CSF) from day 5 until granulocytes were greater than 1.0 × 10 9 /l. G-CSF was not used routinely in patients with AML and CML.
Transplantation procedure
Conditioning regimens consisted of oral BU and intravenous L-PAM. BU was given in four daily doses. The total dose of BU was 560 mg/m 2 (under 5 years of age) or 16 mg/kg. L-PAM was started the day following the last dose of BU at 60 mg/m 2 (before February 1990) or 70 mg/m 2 (after April 1990) (100 mg daily maximum) for 3 consecutive days. Prophylactic phenobarbital or sodium valproate (after 1992) was given for 7 days from the day before BU administration to avoid BU-induced seizures. BMT (day 0) was performed 1 day after the last injection of L-PAM. The median number of nucleated marrow cells infused was 4.1 × 10 8 /kg body weight (range 2.3-5.9 × 10 8 /kg) ( Table 2) . Disease-free survival (DFS) was calculated from the first day of transplant to the time of analysis or the first event.
Informed consent for the transplant procedure was obtained according to the requirements of the ethical committee of the Japanese Red Cross Nagoya First Hospital.
Results

Engraftment
All patients showed durable engraftment. The median time of recovery to WBC у1.0 × 10 9 /l and to granulocytes у0.5 × 10 9 /l for 2 consecutive days was 16 days and 22 days, respectively. The median time to the last platelet transfusion and reticulocyte counts Ͼ1% was 22 days and 17 days, respectively. The use of G-CSF after BMT facilitated the reconstitution of WBC and granulocytes (P Ͻ 0.01) ( Table 2) .
GVHD (Table 3)
Six of 30 patients demonstrated acute GVHD: four had grade I and two had grade II. These children received bolus doses of methylprednisolone (20 mg/kg/day i.v.) or CsA (3 mg/kg i.v.) and had a complete response. Three patients transplanted from phenotypically HLA-identical parents demonstrated no acute or chronic GVHD. A total of eight patients developed chronic GVHD, and five patients developed both acute and chronic GVHD. In all patients chronic GVHD resolved or improved with steroid, CsA or FK506. Two patients have residual impairments (dry eyes in one patient and muscle contraction in a second), although their Karnofsky performance status has remained у90%. The acute and/or chronic GVHD developed in the group who received MTX alone (Figure 1 ).
Toxicity
All patients experienced profound granulocytopenia and thrombocytopenia immediately after BMT, and 17 of 30 patients had pyrexia during this period. Most patients responded to appropriate broad-spectrum antibiotic therapy and became afebrile usually after granulocyte recovery. After hematologic recovery was obtained, five patients demonstrated transient thrombocytopenia (Ͻ50 × 10 9 /l). Vomiting attributable to L-PAM was eliminated or mild in degree with the use of 5-HT 3 receptor antagonists such as granisetron. Stomatitis, vomiting and diarrhea (ϾWHO grade III) were seen in two patients each. Transient elevations of ALT and AST (100 IU/l) were observed in 21 patients (70%), however, these abnormalities improved spontaneously. No patients developed veno-occlusive disease. Varicella zoster virus infection occurred in four patients, and one patient had varicella zoster and herpes simplex virus infection. In four of these five patients the infections were seen after cessation of oral acyclovir. An additional infusion of acyclovir was effective in all cases. Four patients developed bacterial pneumonia which was successfully treated with antibiotics. Four patients developed interstitial pneumonitis. Two patients had idiopathic interstitial pneumonitis which resolved with steroids. Two patients were diagnosed as having CMV pneumonitis with positive CMV antigenemia and were successfully treated with gancyclovir. One patient experienced cardiac failure that improved with diuretics and steroids. Five patients had hemorrhagic cystitis which resolved with conservative therapy. 
Growth post BMT
Twenty-three patients are alive and well more than 3 years after allogeneic BMT. Among them, height was measured in 12 patients at intervals from 2.6 to 8.4 years (median 4.2) after BMT ( Figure 2 
Relapse and causes of death
Three patients relapsed between 5 and 14 months after BMT. One died from disease progression, and the other two patients died of interstitial pneumonitis and obstructive bronchiolitis during CR after second BMT.
Survival
The median follow-up duration for the 30 patients was 59 months (range 9-110). Twenty-seven patients remained disease-free at a median of 61 months (range 22-110) from BMT. The actuarial overall and disease-free survival at 5 years for all patients was 89 and 90%, respectively ( Figure 3) . No relapses occurred later than 2 years post BMT. Seven of eight ALL patients, 18 of 20 AML patients, and both CML patients are alive and relapse-free. All patients in second CR remain disease-free. Of 25 patients with acute leukemia in first CR, three patients relapsed and 22 remain disease-free (88%).
Discussion
The purpose of this study was to evaluate the effectiveness and toxicities of combined high-dose BU and L-PAM for allogeneic BMT in children with good-risk leukemia (acute leukemia in first CR and chronic leukemia in chronic phase). The use of radiation-free conditioning regimens consisting of BU/L-PAM has been previously reported. [13] [14] [15] There are only a few reports of pediatric patients who have undergone allogeneic BMT for leukemia without TBI, 16, 17 particularly when conditioned with BU/L-PAM. The regimen consisting of BU 16 mg/kg and CY 120 mg/kg may be more effective and less toxic than TBI-including regimens. 10 Vassal et al 2 resulted in no life-threatening toxicities, the dosage of L-PAM was raised to 210 mg/m 2 after April 1990. However, there were no increases in serious complications. L-PAM alone results in durable engraftment of allogeneic marrow from HLA-identical siblings. 22 Vey et al 15 have reported engraftment in 24 of 25 patients even at an advanced stage. All our patients had engraftment. This confirms the ability of the BU/L-PAM to allow sustained engraftment in allogeneic BMT.
The incidence of acute and chronic GVHD did not differ significantly between the TBI and non-TBI groups. 16 Eisner and August 23 reported that the incidence of acute GVHD grades II-IV was 32% in children receiving MTX alone as GVHD prophylaxis. Grade II or greater GVHD occurred in only two patients in our series. This lower incidence of acute GVHD in Japanese BMT patients may be attributable, in part, to genetic simplicity. 24 This is in marked contrast to Vey's study 15 that reported grade II or greater acute GVHD in 58% of adult patients. The combination of MTX and CsA usually resulted in a decreased incidence of GVHD and improved survival compared with monotherapy. 25 However, the combination of L-PAM and CsA can be complicated by renal failure. 12 Our study demonstrated that MTX alone is sufficient GVHD prophylaxis. Addition of folinic acid the day after MTX may contribute to reduced toxicity as suggested by Russell et al. 26 BU has been implicated in the development of venoocclusive disease. 27 Although liver function abnormalities were common in our patients, veno-occlusive disease was not seen. This is consistent with the observation that BMT of acute leukemia patients in first remission has been associated with a lesser risk of veno-occlusive disease. 28 Thuret et al 29 have reported diminished severity and frequency of sequelae in children receiving allogeneic BMT in first CR. However, growth impairment appears to occur to a similar degree with both BU/CY and CY/TBI regimens. 30 The children in our series have had acceptable growth impairment, and we continue to monitor their growth.
Allogeneic BMT that includes TBI for childhood AML in first CR has produced post-transplant 5-year DFS rates of 45-80%. 1, 6, 16 The actuarial DFS rates at 3 years for allogeneic BMT using a BU/CY regimen for childhood AML in first CR were 55-82%. 16, 31, 32 The DFS rates in allogeneic BMT for childhood ALL in first CR with TBI and without TBI were 84.4% 33 and 61.9%, 17 respectively. The addition of L-PAM to the BU/CY regimen showed promising results in children with myelodysplastic syndrome. 34 However, this regimen resulted in severe transplant-related toxicity and did not improve event-free survival in childhood ALL. 35 Further trials will be necessary to disclose the efficacy of BU/CY/L-PAM regimen in childhood leukemia. Since Tiedemann et al 36 have reported encouraging results for autologous BMT incorporating high-dose L-PAM, further investigations will be required to see the effectiveness of allogeneic BMT containing L-PAM. The 90% DFS rate and 10% relapse rate in our study are comparable or superior to these other reports. We conclude that allogeneic BMT without TBI in good-risk leukemia patients can achieve good DFS rates with minimal mortality and morbidity. Preparative regimens consisting of high-dose BU/L-PAM are associated with low relapse rates. High-dose BU/L-PAM regimens appear to be of value as conditioning regimens for BMT in childhood leukemia and warrant further clinical trials.
